CN116115680B - External traditional Chinese medicine composition for promoting healing as well as preparation and application thereof - Google Patents
External traditional Chinese medicine composition for promoting healing as well as preparation and application thereof Download PDFInfo
- Publication number
- CN116115680B CN116115680B CN202111346196.6A CN202111346196A CN116115680B CN 116115680 B CN116115680 B CN 116115680B CN 202111346196 A CN202111346196 A CN 202111346196A CN 116115680 B CN116115680 B CN 116115680B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- parts
- promoting
- wound healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000001737 promoting effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000035876 healing Effects 0.000 title abstract description 21
- 230000029663 wound healing Effects 0.000 claims abstract description 23
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 208000015815 Rectal disease Diseases 0.000 claims abstract description 12
- 239000010440 gypsum Substances 0.000 claims abstract description 11
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 11
- 239000000454 talc Substances 0.000 claims abstract description 11
- 235000012222 talc Nutrition 0.000 claims abstract description 11
- 229910052623 talc Inorganic materials 0.000 claims abstract description 11
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940105847 calamine Drugs 0.000 claims abstract description 8
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 8
- 239000011787 zinc oxide Substances 0.000 claims abstract description 8
- 244000146462 Centella asiatica Species 0.000 claims abstract description 3
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 3
- 206010052428 Wound Diseases 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 16
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 14
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 10
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 7
- 229940097275 indigo Drugs 0.000 claims description 7
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 7
- 206010048946 Anal abscess Diseases 0.000 claims description 5
- 241000213006 Angelica dahurica Species 0.000 claims description 5
- 208000004680 Rectal Fistula Diseases 0.000 claims description 5
- 206010002156 anal fistula Diseases 0.000 claims description 5
- 208000014617 hemorrhoid Diseases 0.000 claims description 5
- 241000972673 Phellodendron amurense Species 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 4
- 208000019751 Anorectal disease Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 7
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 abstract description 4
- 241000972672 Phellodendron Species 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 230000023597 hemostasis Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000011160 research Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 241000792859 Enema Species 0.000 description 9
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 9
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 9
- 229940022757 asiaticoside Drugs 0.000 description 9
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000007920 enema Substances 0.000 description 9
- 229940095399 enema Drugs 0.000 description 9
- 210000004400 mucous membrane Anatomy 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010057071 Rectal tenesmus Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 208000012271 tenesmus Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000125175 Angelica Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000032023 Signs and Symptoms Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000027503 bloody stool Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical group [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 201000008267 intestinal tuberculosis Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to an external traditional Chinese medicine composition for promoting healing, and preparation and application thereof. The traditional Chinese medicine composition comprises raw material components including calamine, calcined gypsum, red halloysite, indigo naturalis, talcum, phellodendron, angelica sinensis and centella asiatica. The traditional Chinese medicine composition of the invention aims at simple and low-cost effect, takes 'dampness-astringing and sore-astringing, tissue regeneration promoting and hemostasis' as treatment rules, and has good wound healing effect when the external prescription for promoting healing is used for anorectal diseases.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to an external traditional Chinese medicine composition for promoting healing, and preparation and application thereof.
Background
Diseases of anorectal diseases such as mixed hemorrhoids, perianal abscess, anal fistula and the like, and the wound surface is usually opened after operation. However, due to special anorectal diseases, the postoperative patients need to relieve the bowels, and the wound surface is easy to pollute, so that the problems of wound surface infection, pain, delayed healing and the like are caused. In clinic, the multi-purpose dressing is stuffed to protect the wound surface and diminish inflammation, but the dressing is easy to fall off, the wound surface is still in an exposed state after falling off, and the effects of resisting inflammation and promoting wound surface healing are not satisfactory, and the wound surface is easy to form scars, delay healing and influence the anus function after operation. Therefore, a simple, convenient, low-efficiency and medicine for promoting wound healing of anorectal diseases is urgently needed clinically.
Among anorectal diseases, there is also a special systemic disease called ulcerative colitis. Ulcerative colitis is a chronic nonspecific intestinal inflammatory disease with unknown etiology, and current guidelines propose treatment targets of the disease to maintain clinical relief and mucosal healing, prevent complications and improve the quality of life of patients. The method for clinically treating ulcerative colitis is many, and Western medicine adopts amino salicylic acid, hormone, immunosuppressant, biological agent and the like for treatment, but has uneven curative effect, high price and unsatisfactory remission rate in clinical test, and particularly has obvious side effect after long-term use of the hormone and immunosuppressant, and high recurrence rate after decrement or drug withdrawal. Thus, many patients and medical personnel of ulcerative colitis are focusing on supplemental and alternative medicine. Researches show that the traditional Chinese medicine treatment is the first choice of supplementary and alternative medicine, so that the active research on the traditional Chinese medicine treatment of ulcerative colitis has important social significance and economic benefit.
Disclosure of Invention
In order to overcome the technical problems, the invention aims to provide an external traditional Chinese medicine composition for promoting healing, and preparation and application thereof.
In order to achieve the above and other related objects, the present invention adopts the following technical solutions:
the invention provides a traditional Chinese medicine composition, which comprises the following raw material components in parts by weight:
10-60 parts of calamine, 30-150 parts of calcined gypsum, 10-30 parts of red halloysite, 20-120 parts of natural indigo, 60-150 parts of talcum, 20-80 parts of amur corktree bark, 15-60 parts of Chinese angelica and 15-60 parts of asiaticoside.
Wherein, the Latin name of the calamine is Smithsonite. The Latin name of calcined gypsum is Gypsum Fibrosum Preparatum. Halloysitum rubrum has a Latin name of Halloysitum Rubrum. Latin of Indigo Naturalis is named Indigo Naturalis. Talcum was named as latin. The Latin name of cortex Phellodendri is Cortex Phellodendri. The Latin name of the Chinese angelica is Radix Angelicae Sinensis. Asiaticoside, latin, is named Centella Asiatica (L.) Urban.
Preferably, the traditional Chinese medicine composition comprises the following components in parts by weight: 10-30 parts of calamine, 60-150 parts of calcined gypsum, 10-20 parts of red halloysite, 40-90 parts of natural indigo, 90-120 parts of talcum, 30-80 parts of phellodendron, 30-60 parts of angelica and 30-60 parts of asiaticoside.
More preferably, the traditional Chinese medicine composition comprises the following components in parts by weight: 10-20 parts of calamine, 90-150 parts of calcined gypsum, 10-20 parts of red halloysite, 40-80 parts of natural indigo, 90-120 parts of talcum, 30-60 parts of amur corktree bark, 40-60 parts of Chinese angelica and 30-50 parts of asiaticoside.
The compatibility principle of the traditional Chinese medicine composition of the invention is as follows: the prescription is composed of calamine, calcined gypsum, red halloysite, natural indigo, talcum, phellodendron bark, angelica and asiaticoside. The calamine lotion is used for treating acute pruritus skin diseases such as acute dermatitis, eczema, urticaria and the like. The calcined gypsum has the effects of clearing heat and promoting diuresis, healing sore and promoting granulation, and modern medical research discovers that the calcined gypsum can promote the formation of rat wound fibroblasts, the remodeling of capillaries and the proliferation of granulation tissues, thereby promoting wound healing, and Ca < 2+ > ions in the gypsum can inhibit neuromuscular excitability, reduce vascular permeability and play roles in relieving spasm, impervious, antiallergic and anti-inflammatory. He Shi Zhi is mainly indicated for astringing to stop bleeding, healing sore, promoting granulation, astringing to stop bleeding, because it is sweet in taste, calm in nature, free from jaundice, free from diarrhea and intestinal stasis and purulent blood in five-color Shi Zhi from Shen nong Ben Cao Jing. The natural indigo has the effects of clearing heat and detoxicating, cooling blood and removing freckles, promoting tissue regeneration and relieving pain, and modern medical research shows that the natural indigo can remarkably increase the expression of VEGF and promote the healing of ulcer surfaces. Talc is taken orally to clear summer heat, and is used externally to remove dampness and heal wound, and research shows that Talc has the effects of protecting wound surface, absorbing secretion and promoting crusting. The cortex phellodendri functions of clearing heat and drying dampness, purging intense heat and removing toxin, is mainly used for treating sores and ulcers and eczema wet sores, and can obviously improve local microcirculation, promote granulation tissue growth, repair surface epithelium and accelerate wound healing. The angelica is bitter and sweet in taste, enriches and harmonizes blood, prevents corrosion and promotes tissue regeneration, and has the effects of inhibiting the growth of staphylococcus and bacillus. The asiaticoside has the functions of clearing heat and promoting diuresis, detumescence and detoxification, and modern pharmacological research shows that the asiaticoside is the main active component of the asiaticoside, can promote proliferation of fibroblast and synthesis of collagen, and is mainly used for preventing and treating scar after wound healing and inhibiting scar hyperplasia. The medicines are combined to play the roles of eliminating dampness, promoting wound healing, promoting tissue regeneration and stopping bleeding, and promoting wound healing. The medicines are combined to play the roles of eliminating dampness, promoting wound healing, promoting tissue regeneration and stopping bleeding, and promoting wound healing.
In a second aspect of the present invention, a Chinese medicine extract is provided, which is prepared by extracting the effective components from the above Chinese medicine composition.
In the invention, the raw material components and the formulas thereof in the traditional Chinese medicine composition are the most critical, and after knowing the formulas of the traditional Chinese medicines, the person skilled in the art can directly grind or crush the traditional Chinese medicines according to the proportion and then mix the traditional Chinese medicines as the active ingredients. In addition, the person skilled in the art can also adopt various conventional extraction methods of the effective components of the traditional Chinese medicine to extract the effective components, such as conventional decoction, water extraction and alcohol precipitation methods, alcohol extraction and water precipitation methods, salting-out methods and the like, and the extraction methods can obtain the main effective components in the traditional Chinese medicine formula, so that the traditional Chinese medicine has a certain curative effect on external use and promotion of wound healing.
The water extraction and alcohol precipitation method comprises the following steps: extracting the effective components of the medicinal materials by using water as a solvent, and removing impurities in the extracting solution by using ethanol precipitation with different concentrations. Generally, when the ethanol content reaches 50% -60% (weight/volume ratio, namely g/100 ml), impurities such as starch and the like can be removed, and when the ethanol content reaches more than 75%, most impurities except for few ineffective components such as tannins, water-soluble pigments and the like can be removed by precipitation.
The alcohol extraction and water precipitation method comprises the following steps: extracting the medicinal material components with ethanol with proper concentration, and removing impurities in the extracting solution with water.
The traditional Chinese medicine composition can be concentrated, purified or dried by conventional steps after extracting the effective components to obtain the traditional Chinese medicine extract. Methods of concentration include, but are not limited to: atmospheric pressure evaporation, reduced pressure evaporation, thin film evaporation, multiple effect evaporation, purification methods include, but are not limited to: salting-out purification, macroporous resin adsorption purification, ethanol precipitation purification, ion exchange resin purification, flocculation precipitation purification, membrane separation purification, polyamide adsorption purification, silica gel adsorption chromatography purification and the like, and drying methods include, but are not limited to: drying, drum drying, belt drying, moisture absorption drying, boiling drying, spray drying, reduced pressure drying, freeze drying, infrared drying, microwave drying, etc.
According to the characteristics of the effective components of different crude drugs in the traditional Chinese medicine composition, different extraction processes can be adopted.
Further, in a third aspect of the present invention, there is also provided a method for preparing a Chinese medicinal extract, the method comprising the steps of: the preparation method comprises mixing the above Chinese medicinal materials, grinding or pulverizing, and mixing.
Preferably, each traditional Chinese medicine component is crushed into 100-300 meshes.
In a fourth aspect of the invention, the application of a traditional Chinese medicine composition or a traditional Chinese medicine extract in preparing a wound healing medicine is provided.
Further, the wound surface refers to postoperative wound surfaces of ulcerative colitis, mixed hemorrhoids, anal fistula and perianal abscess.
In a fifth aspect of the present invention, there is further provided a Chinese medicinal preparation comprising a therapeutically effective amount of the foregoing Chinese medicinal extract and one or more conventional pharmaceutically acceptable excipients.
After extracting the effective components in the traditional Chinese medicine composition, the traditional Chinese medicine composition can be prepared into a traditional Chinese medicine preparation by adopting conventional pharmaceutical auxiliary materials and additives.
Pharmaceutically acceptable excipients include (but are not limited to): pharmaceutically acceptable carriers, diluents, fillers, binders and other excipients. Therapeutically inert inorganic or organic carriers known to those skilled in the art include, but are not limited to, lactose, corn starch or derivatives thereof, talc, vegetable oils, waxes, fats, poly-antelope based compounds such as polyethylene glycols, water, sucrose, ethanol, glycerol and the like, various preservatives, lubricants, dispersants, flavoring agents. Humectants, antioxidants, sweeteners, colorants, stabilizers, salts, buffers and the like may also be added thereto as needed to aid stability of the formulation or to aid in enhancing activity or its bioavailability or to produce an acceptable mouthfeel or odor in the case of oral administration. Traditional Chinese medicine preparations such as granules and ointments can be prepared by conventional methods. The pharmaceutical compositions of the present invention may also be used with other therapeutic agents.
Preferably, the Chinese medicinal preparation is an external preparation. The auxiliary material is solvent. For example, the solvent may be sesame oil. The sesame oil not only can enable the medicine to adhere to the straight colon, but also can promote wound healing.
In addition, in addition to the use of sesame oil as a solvent for the preparation, can also use 0.9% sodium chloride injection or medical water.
The effective therapeutic dose of the traditional Chinese medicine preparation is that the effective dose is usually 0.1-0.2 g/kg body weight for each use by the total weight of the raw medicinal materials, and the effective dose is used for 2 times a day. Of course, the particular dosage should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled practitioner.
Compared with the prior art, the invention has the beneficial effects that: the invention has the advantages of convenient administration route, fewer components, simple preparation, low price and good effect, and can be used by patients at home, thereby being beneficial to industrial production. Compared with the existing medicines, the traditional Chinese medicine has incomparable advantages including effective control of inflammation and promotion of wound healing.
Detailed Description
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention. The test methods in the following examples, in which specific conditions are not noted, are generally conducted under conventional conditions or under conditions recommended by the respective manufacturers.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, materials used in the embodiments, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present invention may be used to practice the present invention according to the knowledge of one skilled in the art and the description of the present invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all employ techniques conventional in the art.
The raw materials (or medicinal materials) adopted by the invention can be purchased from common medical shops or Chinese medicinal material selling companies, and the specification of the raw materials (or medicinal materials) accords with the national medical standard or the related regulations of Chinese pharmacopoeia and the like. The adopted medicinal materials are all Chinese medicinal material decoction pieces unless otherwise indicated, and the Chinese medicinal material decoction pieces can also be obtained and processed.
The curative effect standard of the invention refers to the relevant curative effect standard in the traditional Chinese medicine disease judgment curative effect standard. And (3) healing: all clinical symptoms disappeared and laboratory examination was normal. Improvement: clinical symptoms are reduced, laboratory tests are improved or normal. Invalidation: the clinical symptoms are not obviously improved or aggravated.
The preparation process of the invention basically uses the technical requirement of the preparation process research of new traditional Chinese medicines, extracts main active ingredients of the medicines by using the new technology of modern preparations, and adds some pharmaceutically acceptable auxiliary materials or carriers.
Example 1
The embodiment 1 provides the raw material components and the weight part ratio thereof in the traditional Chinese medicine composition.
TABLE 1
| Formulation 1 | Formulation 2 | Formulation 3 | Formulation 4 | Formulation 5 | Formulation 6 | Comparative example 1 | |
| Calamine (g) | 15 | 10 | 20 | 30 | 60 | 40 | 7.5 |
| Calcined gypsum (g) | 135 | 90 | 150 | 60 | 30 | 60 | 10.5 |
| Halloysitum rubrum (g) | 15 | 20 | 10 | 20 | 30 | 25 | 7.5 |
| Indigo naturalis (g) | 60 | 80 | 40 | 90 | 120 | 20 | 50 |
| Talc (g) | 120 | 90 | 120 | 120 | 150 | 60 | 100 |
| Cortex phellodendri (g) | 60 | 30 | 60 | 80 | 20 | 20 | 50 |
| Chinese angelica (g) | 45 | 60 | 40 | 30 | 15 | 40 | 0 |
| Asiaticoside(g) | 45 | 50 | 30 | 60 | 15 | 50 | 0 |
The preparation method comprises the following steps:
according to Table 1, the raw materials in formulas 1-6 and comparative formula 1 are ground into powder, sieved by a 100-300 mesh sieve for 2 times, and mixed with sesame oil to prepare an ointment. And (5) standby application.
Example 2
This example 2 was used to verify the therapeutic effect of formulations 1-6 and comparative formulation 1 prepared in example 1.
Ulcerative colitis is a nonspecific inflammatory bowel disease that changes with continuous and diffuse inflammation of the colorectal mucosa, with lesions mainly in the rectum and sigmoid colon, severely affecting the whole colon. The clinical manifestations of the traditional Chinese medicine are diarrhea, mucopurulent bloody stool, abdominal pain and tenesmus. Ulcerative colitis has unknown etiology, long disease course, easy repeated disease, easy canceration and no cure. And epidemiological researches in China show that the incidence rate of UC is continuously rising in the last 20 years. The current therapeutic goal of UC is to induce and maintain clinical relief and mucosal healing, prevent complications, improve patient quality of life, and enhance long-term management. The method for clinically treating the ulcerative colitis is many, the Western medicine is mostly treated by adopting amino salicylic acid, hormone, immunosuppressant, biological preparation and the like, but the curative effect is uneven, the price is high, and especially the side effect is obvious after the hormone and the immunosuppressant are used for a long time, and the recurrence rate is high after the reduction or stopping of the medicine. Some patients with ulcerative colitis in the outpatient department of the me have abdominal pain, diarrhea and mucopurulent blood, so that the patients are convenient for the department of the me to visit, and the patients are insensitive to western medicines (mesalamine and the like) and have insignificant curative effects. The cure promoting topical formulations of formulas 1-6 prepared in example 1 were applied to a sui me family to preserve the enema and comparative example 1 was used as a control.
(one), general data
56 patients with ulcerative colitis, aged 18-70 years, 34 men and 22 women.
(II) diagnostic criteria
1. Disease diagnosis criteria
According to the consensus opinion of diagnosis and treatment of inflammatory bowel disease made by the digestive society of medical science of China, the digestive society of medical science, the inflammatory bowel disease, the 2018:
(1) Clinical manifestations: continuous or repeated diarrhea, mucopurulent bloody stool with abdominal pain, tenesmus and systemic symptoms with different degrees, and the disease course is more than 4-6 weeks; can be used for treating intestinal external manifestations such as skin, mucous membrane, joint, eye, liver and gallbladder.
(2) Enteroscopy: mucosal congestion and vascular texture vanish; bleeding, erosion and bleeding are visible on the mucosal surface; it can be seen that the colonic band morphology disappeared, the intestinal lumen was narrow and the inflammatory polyp.
2. Severity of activity
A modified Mayo scoring system was used. (see Table 2)
Table 2 improved Mayo score
Note that: 1) Each subject served as a self-control to evaluate the degree of abnormality in the number of bowel movements; 2) Daily bleeding scores represent the most severe bleeding cases in 1 day; 3) Physician population evaluation included 3 criteria: review of abdominal discomfort, overall well-being, and other manifestations of the subject, such as physical examination findings and subject performance status.
Scoring criteria: mild activity: 3-5 is divided into; moderate activity: 6-10 minutes; heavy activities: 11-12 minutes.
3. Clinical symptom classification
Clinical symptoms are classified according to the guidelines of clinical research of new traditional Chinese medicines, wherein the main symptoms (abdominal pain, diarrhea and mucopurulent bloody stool) are respectively 0, 3, 6 and 9 minutes according to the weight of the Chinese medicine, and the secondary symptoms (tenesmus, abdominal distension, anorexia and hypodynamia) are respectively 0, 1, 2 and 3 minutes. (see Table 3)
TABLE 3 clinical symptoms grading score
4. Inclusion criteria
(1) Meets the diagnostic criteria;
(2) diagnosing mild or moderate activity according to the modified Mayo scoring system;
(3) insensitive or resistant to mesalamine treatment;
(4) age 18-70 years;
(5) the patient informed the study and signed informed consent.
5. Exclusion and rejection criteria
(1) Serious complications such as intestinal perforation, intestinal cancer and other diseases;
(2) there are bacillary dysentery, intestinal tuberculosis, crohn's disease, ischemic colitis, etc.;
(3) patients with heart, brain, liver, kidney and other important organ diseases;
(4) pregnant and lactating women;
(5) allergic constitution and allergic to various drugs;
(6) refusing to sign informed consent or being unable to follow the order for the therapist.
(III), grouping and treatment
The 56 patients screened were randomly divided into seven groups.
56 patients, 18-70 years old, 34 men and 22 women.
A first group: patient 8, male 5, female 3, patient were given formulation 1 prepared as in example 1, specific usage: enema was performed in the morning and evening for 4 weeks.
Second group: patient 8, male 6, female 2, patient was given formulation 2 prepared as in example 1, with specific usage: enema was performed in the morning and evening for 4 weeks.
Third group: patient 8, male 4, female 4, patient was given formulation 3 prepared as in example 1, specific usage: enema was performed in the morning and evening for 4 weeks.
Fourth group: patient 8, male 6, female 2, patient was given formulation 4 prepared as in example 1, with specific usage: enema was performed in the morning and evening for 4 weeks.
Fifth group: patient 8, male 5, female 3, patient were given formulation 5 prepared as in example 1, with specific usage: enema was performed in the morning and evening for 4 weeks.
Sixth group: patient 8, male 4, female 4, patient was given formulation 6 prepared as in example 1, with specific usage: enema was performed in the morning and evening for 4 weeks.
Comparison group: patient 8, male 4, female 4, patient were given a comparative example 1 prepared as in example 1, specific usage: enema was performed in the morning and evening for 4 weeks.
(IV) observing the index
Therapeutic efficacy index
1. Assessment of clinical symptom stratification before and after treatment
Clinical symptom grading standard refers to curative effect evaluation standard in clinical research guidelines for chronic nonspecific ulcerative colitis in the guidelines for clinical research on New Chinese medicine:
clinical alleviation: before and after administration, symptoms and signs are obviously improved (the curative effect index is more than or equal to 95 percent);
the effect is shown: after taking the medicine, the symptoms and the signs are obviously improved (the curative effect index is less than or equal to 70 percent and less than 95 percent);
the method is effective: after taking the medicine, symptoms and signs are improved (the curative effect index is less than or equal to 30 percent and less than 70 percent);
invalidation: after administration, symptoms and signs were not significantly reduced or aggravated (efficacy index < 30%).
The calculation formula (nimodipine method) is: efficacy index% = (pre-treatment integral-post-treatment integral)/pre-treatment integral x 100%.
2. Anoscope observes the rectal mucosa before and after treatment.
3. The peripheral serum cytokines TNF-alpha and IL-6 were tested before and after administration to the patient.
(V) treatment results
The external prescription 1 for promoting healing in the embodiment 1 has obvious clinical curative effect, and after 1-2 weeks of enema treatment, the mucopurulent blood is obviously reduced under the anoscope, the mucous membrane color is changed from red to light, and the pain, diarrhea and tenesmus of patients are obviously relieved. Through clinical symptom classification, the obvious effect rate is up to 100%. Of these, 5 patients were reviewed for significant earlier decrease in peripheral serum cytokines TNF- α and IL-6. Fully explain: the external prescription for promoting healing can effectively relieve and treat intestinal inflammation and accelerate mucous membrane healing.
In addition, after treatment for 4 weeks in the formula 2 and the formula 3, the mucopurulent blood is obviously reduced under the anoscope, the mucous membrane color turns light, the patient complains about abdominal pain and diarrhea is relieved, but the effective rate is 87.5% compared with the formula 1, the effective rate of the formula 2 is 75%, and the effective rate of the formula 3 is 62.5%.
After the formula 4 is treated for 4 weeks, the abdominal pain of the patient is relieved, the symptoms of mucopurulent blood are improved, the color of mucous membrane is turned light under the anoscope, the yellow clear mucous is more, the effective rate is 87.5%, and the obvious rate is 50%.
After treatment for 4 weeks in the formula 5 and the formula 6, symptoms of abdominal pain and diarrhea of patients can be obviously improved, the improvement of the heavy sensation after tenesmus is not obvious, the anoscope is slightly improved before the mucous membrane is seen, and the pus blood is reduced. The effective rate of the formula 5 is 62.5%, and the obvious rate is 37.5%. The effective rate of the formula 6 is 50%, and the obvious efficiency is 37.5%.
The treatment effect of comparative example 1 is that the abdominal pain and diarrhea of the patient are slightly improved, the heavy feeling after tenesmus is still obvious, the mucous and purulent blood under the anoscope are slightly improved than before, the effective rate is 37.5%, and the obvious rate is 12.5%.
Further, the pre-experiment of the DSS modeling ulcerative colitis mice is applied, and the colon pathological change is observed through the external prescription of stomach irrigation and healing promotion. The intestinal mucosa epithelium tissue of the normal control group is complete, the arrangement is neat, the structure is clear, and the gland is complete. Model group intestinal mucosa epithelium is broken, shed, intestinal mucosa is engorged with congestion and edema, and lamina propria inflammatory cells infiltrate.
Model mice were randomly divided into 7 groups using formulations 1-6 and comparative formulation 1 prepared as in example 1, respectively, using the following methods: mice were anesthetized for 1h, clysis, and continued for 1 week in the morning and evening.
As a result, it was revealed that the partial mucosal epithelial cells of formulas 1 to 6 (ex. Promoting formulation) were disrupted, the intestinal wall was thickened, the glandular structure was substantially clear and intact, and the lamina propria had inflammatory cell infiltration, wherein the effect of formula 1 was optimal. Fully explain: the external prescription for promoting healing can effectively relieve inflammation and maintain the structural integrity of glands. And the effect of the formula 1-3 is better than that of the formula 4-6.
In addition, formulas 1-6 were significantly better than control 1, which exhibited fragmentation of the intestinal mucosa epithelium, congestion edema of the intestinal mucosa, and inflammatory cell infiltration of the lamina propria, with an effect similar to that of the model group.
Example 3
Formulations 1-6 of example 1 and comparative example 1 were used to try to treat post-operative wounds of mixed hemorrhoids, anal fistula, perianal abscess, respectively. The results were: compared with a blank control group, the formula 1-3 accelerates the wound healing, wherein the formula 1 has particularly remarkable effect, the granulation starts to grow in pink 3-5 days after operation, the substrate is firm, the epithelial tissue at the edge of the wound starts to creep in 7-10 days after operation, the matching degree of the granulation and the epithelial creeping is high, and the wound heals normally. The accelerating ability of the formula 4-6 is slightly inferior to that of the formula 1-3, and the granulation and the epithelial tissues at the edge of the wound are slower than those of the formula 1-4 days before, but no poor growth or delayed healing of the wound occurs. The effect of the comparative example 1 on accelerating the wound healing after anal fistula operation is the same as that of formulas 4-6, but the wound healing condition after mixed hemorrhoids and perianal abscess operation is the same as that of a blank control group, and adverse events such as loose and high granulation, bright edema, pale color, scarlet and the like are also the same as that of the blank control group.
The above embodiments are merely illustrative of the principles of the present invention and its effectiveness, and are not intended to limit the invention. Modifications and variations may be made to the above-described embodiments by those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is intended that all equivalent modifications and variations of the invention be covered by the claims, which are within the ordinary skill of the art, be within the spirit and scope of the present disclosure.
Claims (7)
1. A traditional Chinese medicine composition for external use for promoting wound healing of anorectal diseases comprises the following raw material components in parts by weight: 10-20 parts of calamine, 90-150 parts of calcined gypsum, 10-20 parts of red halloysite, 40-80 parts of natural indigo, 90-120 parts of talcum, 30-60 parts of amur corktree bark, 40-60 parts of Chinese angelica, and 30-50 parts of centella asiatica.
2. A topical Chinese medicinal extract for promoting wound healing of anorectal diseases is prepared by extracting effective components from the Chinese medicinal composition as claimed in claim 1.
3. A method for preparing the external traditional Chinese medicine extract for promoting anorectal disease wound healing according to claim 2, comprising the steps of: the traditional Chinese medicine components are taken according to the proportion, and are evenly ground or crushed and then mixed.
4. A method according to claim 3, wherein the individual components of the traditional Chinese medicine are crushed to a particle size of 100-300 mesh.
5. The use of the external traditional Chinese medicine composition for promoting anorectal disease wound healing according to claim 1 or the traditional Chinese medicine extract according to claim 2 in preparing the external medicine for promoting anorectal disease wound healing.
6. The use according to claim 5, wherein the wound is a post-operative wound of ulcerative colitis, mixed hemorrhoids, anal fistula, perianal abscess.
7. A Chinese medicinal external preparation for promoting anorectal diseases wound healing, which is prepared from a therapeutically effective amount of the external Chinese medicinal extract for promoting anorectal diseases wound healing as claimed in claim 2 and one or more conventional pharmaceutically acceptable auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111346196.6A CN116115680B (en) | 2021-11-15 | 2021-11-15 | External traditional Chinese medicine composition for promoting healing as well as preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111346196.6A CN116115680B (en) | 2021-11-15 | 2021-11-15 | External traditional Chinese medicine composition for promoting healing as well as preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116115680A CN116115680A (en) | 2023-05-16 |
| CN116115680B true CN116115680B (en) | 2024-04-05 |
Family
ID=86306732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111346196.6A Active CN116115680B (en) | 2021-11-15 | 2021-11-15 | External traditional Chinese medicine composition for promoting healing as well as preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116115680B (en) |
-
2021
- 2021-11-15 CN CN202111346196.6A patent/CN116115680B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 梅全喜.《现代中药药理与临床应用手册》.中国中医药出版社,2016,(第3版),第922页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116115680A (en) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100455311C (en) | Composition of Chinese traditional medicine in use for treating burn and scald, and product for resolving poxes, and preparation method | |
| CN108653479A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating refractory skin | |
| CN107213402B (en) | Binghuang hemorrhoids ointment | |
| CN116115680B (en) | External traditional Chinese medicine composition for promoting healing as well as preparation and application thereof | |
| CN113616714A (en) | High-selenium anti-HPV (human papillomavirus) biological protein gel dressing and preparation method thereof | |
| CN103893495A (en) | Traditional Chinese medicine liquid for treating skin itch and preparation method | |
| CN104840623A (en) | Traditional Chinese medicine combination for treating toxic heat flourishing type burn and preparation method thereof | |
| CN104523912A (en) | Pharmaceutical composition treating anorectal diseases, and preparation method and application thereof | |
| CN108310218B (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method and application thereof | |
| CN108785559B (en) | Medicine for treating respiratory tract infection and preparation method thereof | |
| CN1418674A (en) | Medicine compositions for treating acne, and its prepn. method | |
| CN111568932B (en) | External pain-relieving and bleeding-stopping pharmaceutical composition and preparation method and application thereof | |
| CN100409885C (en) | Medicine for treating proganital lichen sclerosus disease | |
| CN110559374A (en) | medicine for resisting HPV infection and preparation method thereof | |
| CN102178732B (en) | Chinese medicine nanoemulsion spraying agent for treating chronic eczema | |
| CN114028487B (en) | Pharmaceutical composition and preparation for treating acute soft tissue injury | |
| CN104706914B (en) | A kind of Chinese medicine and preparation method for the treatment of bacterial vaginitis | |
| CN108514640A (en) | Medical composition and its use containing pokeweed antiviral protein and immunologic active material | |
| CN111494571B (en) | Traditional Chinese medicine composition for treating damp-heat blockage type gout and preparation method thereof | |
| CN116077564B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hemorrhoids | |
| CN113893287B (en) | External traditional Chinese medicine preparation for treating eczema | |
| CN117503694A (en) | Traditional Chinese medicine ointment for promoting wound healing after anal fistula or perianal abscess operation | |
| CN114948977B (en) | Application of dihydroflavonoid glycoside derivative in preparation of medicines for preventing and treating colonitis | |
| CN107080762B (en) | Application of sweet potato as medicine for treating hemorrhoids | |
| CN117045745A (en) | Traditional Chinese medicine composition for treating anal fissure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |